Compare OGN & AGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGN | AGM |
|---|---|---|
| Founded | 1923 | 1987 |
| Country | United States | United States |
| Employees | N/A | 212 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2020 | N/A |
| Metric | OGN | AGM |
|---|---|---|
| Price | $6.11 | $143.35 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $11.75 | ★ $215.00 |
| AVG Volume (30 Days) | ★ 3.0M | 88.5K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | 1.33% | ★ 4.56% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $6,216,000,000.00 | N/A |
| Revenue This Year | $0.42 | $24.86 |
| Revenue Next Year | $1.67 | $10.89 |
| P/E Ratio | ★ $8.38 | $9.95 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.03 | $136.57 |
| 52 Week High | $15.36 | $210.64 |
| Indicator | OGN | AGM |
|---|---|---|
| Relative Strength Index (RSI) | 29.92 | 32.45 |
| Support Level | N/A | N/A |
| Resistance Level | $7.87 | $164.32 |
| Average True Range (ATR) | 0.21 | 4.91 |
| MACD | -0.01 | -1.29 |
| Stochastic Oscillator | 26.54 | 24.59 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven reportable segments: Farm & Ranch, which generates maximum revenue, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA. Geographically, the company's operations are spread across different regions in the United States.